Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MONTBLANC: Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma
2022-001201-48Phase 2Active
- Sponsor
- LMU Klinikum
- Start
- Oct 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, tremelimumab and bevacizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by LMU Klinikum. Primary endpoint: ORR (objective response rate). Started Oct 2022; status: active.
02
Drugs
durvalumabtremelimumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2022-001201-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001201-48.